AACR 2024 | CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar, MBBS, Sarcoma Oncology Research Center, Santa Monica, CA, discusses findings from an analysis of CCNG1 expression in 137 patients across various cancer types treated with DRG-101, a tumor-targeted retrovector. All tumors exhibited enhanced CCNG1 expression, with varying levels across patients. Notably, patients with sustained remission from metastatic pancreatic cancer and breast cancer showed specific CCNG1 expression levels. DRG-101 additionally has potential in combination therapy for advanced pancreatic cancer, sarcoma, and breast carcinoma. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
DRG-101 is also known as DeltaRex-G. So it is a tumor targeted retro vector encoding CCNG1 inhibitor gene, and CCNG1 is basically a non-canonical cyclin. So our poster is basically about utilizing DeltaRex-G in patients with advanced pancreatic cancer, advanced sarcomas and breast cancer, to see which patients would respond favorably to DeltaRex-G. We test them for levels of CCNG1 expression. Previously we reported, that all sarcoma tumors have enhanced CCNG1 expression...
DRG-101 is also known as DeltaRex-G. So it is a tumor targeted retro vector encoding CCNG1 inhibitor gene, and CCNG1 is basically a non-canonical cyclin. So our poster is basically about utilizing DeltaRex-G in patients with advanced pancreatic cancer, advanced sarcomas and breast cancer, to see which patients would respond favorably to DeltaRex-G. We test them for levels of CCNG1 expression. Previously we reported, that all sarcoma tumors have enhanced CCNG1 expression. So in this report, we have our expanded our analysis to 137 patients with other cancer types. And our results show that 100% tumors basically have enhanced CCNG1 expression. So this tells us that DeltaRex-G has potential of platform therapy upon which other FDA approved cancer drugs can be added. And DeltaRex-G is promising therapy for, um, basically even advanced pancreatic cancer, sarcomas and breast cancer. We have patients with prolonged survival who have been on DeltaRex-G as monotherapy. So it looks great. And DeltaRex-G is not sponsored by any pharma companies or insurance companies. It is basically provided by Aveni Foundation, which is a charity that is that runs on generous donations of benefactors. So, uh, we do encourage donations to Aveni Foundation.
Read more...
